BioCryst Pharmaceuticals, Inc. stock is up 9.04% since 30 days ago. The next earnings date is Feb 20, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 46.67% of the previous 29 December’s closed higher than November. 100% of analysts rate it a buy.
BioCryst Pharmaceuticals, Inc. discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases. Galidesivir, a RNA dependent-RNA polymerase inhibitor, is in clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola,